Craft
Nouscom

Nouscom

Total Funding

$62.6 M

Nouscom Summary

Company summary

Overview
Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.
Type
Private
Status
Active
Founded
2015
HQ
Basel, CH | view all locations
Website
http://nouscom.com/
Cybersecurity rating
Sectors

Key people

  • Riccardo Cortese

    Riccardo Cortese, Co-Founder

    • Elisa Scarselli

      Elisa Scarselli, Chief Scientific Officer and Co-Founder

      • Marina Udier

        Marina Udier, Chief Executive Officer & Board Director

        • Stefano Colloca

          Stefano Colloca, Co-Founder & Advisor

          LocationsView all

          2 locations detected

          • Basel, Basel-Stadt HQ

            Switzerland

            18 Bäumleingasse

          • Roma, Lazio

            Italy

            100 Via di Castel Romano

          Footer menu